



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	IO. FILING DATE FIRST NAMED INVES		ATTORNEY DOCKET NO.	KET NO. CONFIRMATION NO.
10/038,722	01/08/2002	Arthur Charles Ley	LEY=1B 4070 EXAMINER	
23628 759	90 07/15/2005			
WOLF GREENFIELD & SACKS, PC FEDERAL RESERVE PLAZA			MOORE, WILLIAM W	
600 ATLANTIC	<del></del>		ART UNIT	PAPER NUMBER
BOSTON, MA	02210-2211		1656	
			DATE MAILED: 07/15/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Supplemental Notice of Allowability

$\sim$		
Application No.	Applicant(s)	
10/038,722	LEY ET AL.	
Examiner	Art Unit	
William W. Moore	1656	

Notice of Allowability	otice of Allowability Examiner Art Unit		
	William W. Moore	1656	
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI- of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apport or other appropriate communication GHTS. This application is subject to	plication. If not includ will be mailed in due	led course. THIS
1. 🖾 This communication is responsive to the interview conducted	ed 11 July 2005.		
2. ⊠ The allowed claim(s) is/are <u>43-52</u> .			
3. The drawings filed on are accepted by the Examiner	:		
4. ☐ Acknowledgment is made of a claim for foreign priority un  a) ☐ All b) ☐ Some* c) ☐ None of the:  1. ☐ Certified copies of the priority documents have  2. ☐ Certified copies of the priority documents have  3. ☐ Copies of the certified copies of the priority documents have  3. ☐ Copies of the certified copies of the priority documents have  3. ☐ Copies of the certified copies of the priority documents have  4. ☐ Copies of the priority documents have  5. ☐ Applicant has THREE MONTHS FROM THE "MAILING DATE" of the noted below. Failure to timely comply will result in ABANDONMING THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted in INFORMAL PATENT APPLICATION (PTO-152) which give to CORRECTED DRAWINGS (as "replacement sheets") must (a) ☐ including changes required by the Notice of Draftsperson to Paper No./Mail Date	been received.  been received in Application Nocuments have been received in this recei	national stage applicational stage application of the complying with the results of the complying with the results of the complex of the comp	quirements
(b) including changes required by the attached Examiner's Paper No./Mail Date  Identifying indicla such as the application number (see 37 CFR 1.4 each sheet. Replacement sheet(s) should be labeled as such in the	84(c)) should be written on the drawin	gs in the front (not the	ə back) of
<ol> <li>DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT F</li> </ol>			Note the
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit	<u> </u>	(PTO-413), e nent/Comment	,
4. பு Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ⊠ Examiner's Stateme 9. □ Other	iii oi reasons ior Alio	owance

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04) Application/Control Number: 10/038,722

**Art Unit: 1656** 

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Rewrite claims 51 and 52 thus:

- 51. (Amended) A method of treating emphysema in a subject which comprises administering to the subject a therapeutically effective amount of a polypeptide of any one of claims 43-48.
- 52. (Amended) A method of treating cystic fibrosis in a subject which comprises administering to the subject a therapeutically effective amount of a polypeptide of <a href="mailto:any-one-of-claims">any-one-of-claims</a> 43-48.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Michael T. Siekman on 12 July 2005.

The following is an examiner's statement of reasons for allowance:

The above amendment clarifies the recitations of claims 51 and 52 by inserting the phrase "any one of" as it appears in the preceding claims 59 and 50 submitted in the amendment filed 18 April 2005.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## Conclusion

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1656

Any inquiry concerning this communication or earlier communications from the examiner should be directed to William W. Moore whose telephone number is 571.272.0933 and whose FAX number is 571.273.0933. The examiner can normally be reached Monday through Friday between 9:00AM and 5:30PM EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's Supervisory Primary Examiner, Dr. Kathleen Kerr, can be reached at 571.272.0931. The official FAX number for all communications for the organization where this application or proceeding is assigned is 571.273.8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571.272.1600.

William W. Moore 12 July 2005

> KATHLEEN M. KERR, PH.D. SUPERVISORY PATENT EXAMINER